Gastric Cancer | Clinical

January 20, 2023

The combination of zolbetuximab and mFOLFOX6 prolonged survival in patients with CLDN18.2+ advanced gastric gastroesophageal junction adenocarcinoma, according to the phase 3 data from the SPOTLIGHT trial.

January 19, 2023

Findings presented at the 2022 Gastrointestinal Cancers Symposium warrant the need for new treatments that attack HER2-low advanced gastric cancer.

December 19, 2022

Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

December 15, 2022

During a live event, Manish A. Shah, MD, discussed the case of a 65-year-old man presented with new onset fatigue, upper abdominal pain that worsened with eating, and unintentional weight loss.

December 09, 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.

November 25, 2022

During a Targeted Oncology case-based roundtable event, May Cho, MD, discussed with participants how their practice is impacted by the introduction of trastuzumab deruxtecan for HER2+ gastric cancer.

November 18, 2022

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.

November 17, 2022

Initial results from the phase 3 spotlight study show that the study met its primary and key secondary end point of progression-free and overall survival.

October 31, 2022

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

October 31, 2022

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.